ADVANZ PHARMA Corp. Limited (TSX:ADVZ) will look for acquisitions. Graeme Duncan, Chief Executive Officer said, “In the second quarter, the portfolio of niche medicines from Correvio contributed approximately $3 million in topline revenue to ADVANZ PHARMA. We've also made significant progress towards the achievement of synergies on the Correvio acquisition. We continue to expect that on a pro forma basis, Correvio will be a profitable business in 2020. With a robust global M&A platform and supported stakeholders, we remain focused on actively assessing a number of potentially attractive product acquisition opportunities. We are encouraged to see that the M&A pipeline continues to expand and are confident that we are in a strong position to continue to execute on our M&A priorities going forward”.